Latest Breaking News On - Axel lehrer - Page 1 : comparemela.com

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.

United statesWhite houseDistrict of columbiaEquatorial guineaLos cabosAxel lehrerSoligenix incCenters for diseaseVaccine technologyExchange commissionJohna burns school medicineUs congressOur public health solutionsVaccine technology ix conferenceCompany public health solutionsVaccine technology conference

Soligenix extends patent protection for its filovirus vaccine platform to the UK and South Africa

Soligenix announced it has received notice of intent to grant additional patents based on its patent application in the UK and South Africa.

United statesUnited kingdomSouth africaAxel lehrerOreola doniniSmall business innovation researchNational institute of healthUniversity of hawaiiCompany public health solutionsJohna burns school of medicineManufacturing trivalent filovirusAssociate professorSenior vice presidentChief scientific officerPublic health solutionsNational institute

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomEquatorial guineaSouth africaUnited statesWhite houseDistrict of columbiaOreola doniniAxel lehrerDevelopment authoritySmall business innovation researchUs congressExchange commissionBiomedical advanced researchJohna burns school of medicineNational institute of allergyCompany public health solutions

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.

United statesAxel lehrerOreola doniniOur public health solutionsUs congressExchange commissionSoligenix incDrug administrationDefense threat reduction agencyNational institute of allergyCenters for diseaseBiomedical advanced researchPrnewswire soligenix incDevelopment authorityUniversity of hawaiProvides suvax

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Single-vial thermostabilized bivalent vaccine demonstrates simultaneous protection against two lethal viruses PRINCETON, N.J., Jan. 2, 2024 /PRNewswire/ Soligenix, Inc. , a late-stage.

United statesUniversity of hawaii at manoaAxel lehrerOreola doniniPrnewswire soligenix incDepartment of tropical medicineCompany public health solutionsUs developmentOur public health solutionsNational institute of allergySoligenix incSmall business innovation researchUs congressUniversity of hawaiJohna burns school of medicineBiomedical advanced research